Wednesday, 24 May 2017

Clearsynth introduces High-Field Bio NMR facility at Hyderabad

11 May 2017 | News

The spectrometer is ideally suited for solution-state NMR studies on biological macromolecules like proteins and nucleic acids

Clearsynth announces the establishment of High-Field Bio NMR/ 600 MHz facility at its R&D LAB in Hyderabad. The ultrashield instrument would give scientists an easier and quicker way of quantitative analysis like never before. With the opening of this facility, the company aims to provide world class NMR service and develop research collaboration for protein therapeutics and biosimilar service.

The spectrometer is ideally suited for solution-state NMR studies on biological macromolecules like proteins and nucleic acids. The well-equipped facility is likely to be one stop solution for challenges in biologics; biosimilars, pharmaceuticals, API Generics, Nutraceuticals and Allied Healthcare Products. It would address all the challenges associated with the quality control, product stability and regulatory requirements. The advanced facility is going to be functional very soon.

Clearsynth state of art R&D center at Hyderabad is cGMP compliant and accredited with ISO 9001: 2008 (Quality Management System), ISO 14001:2004 (Environmental Management System) and OHSAS 18001: 2007 (Health & Safety Management System) standards. The laboratory is well equipped with modern analytical instruments (Fume hoods, NMR, GC, LC MSMS, IR/UV, TGA, DSC, Prep HPLC, Flash Chromatography). The new 600MHZ BioNMR spectroscopy would provide competitive advantage and also direct research to greater heights.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

How important is the procurement function in any organisation?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls